Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Autor: | Garvey, W. Timothy, Batterham, Rachel L., Bhatta, Meena, Buscemi, Silvio, Christensen, Louise N., Frías, Juan Pablo, Jódar Gimeno, José Esteban, Kandler, Kristian, Rigas, Georgia, STEP 5 Study Group |
---|---|
Přispěvatelé: | Garvey, W Timothy, Batterham, Rachel L, Bhatta, Meena, Buscemi, Silvio, Christensen, Louise N, Frias, Juan P, Jódar, Esteban, Kandler, Kristian, Rigas, Georgia, Wadden, Thomas A, Wharton, Sean |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Adult
Male Glucagon-Like Peptide Hypoglycemic Agent Obesidad Investigación médica General Medicine Middle Aged Overweight Weight Lo General Biochemistry Genetics and Molecular Biology Tratamiento médico Treatment Outcome Double-Blind Method Diabetes Mellitus Type 2 Glucemia Control glucémico Female Obesity Settore MED/49 - Scienze Tecniche Dietetiche Applicate Human |
ISSN: | 0369-3430 |
Popis: | The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit). Most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m–2 and weight of 106.0 (22.0) kg. The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group (n = 152) versus −2.6% with placebo (n = 152), for an estimated treatment difference of −12.6 %-points (95% confidence interval, −15.3 to −9.8; P P |
Databáze: | OpenAIRE |
Externí odkaz: |